Ocugen, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Ocugen disclosed clinical and regulatory progress across three ophthalmology gene therapy programs: OCU400 (retinitis pigmentosa, 100+ genes, Phase 3 enrollment complete, topline 2027), OCU410ST (Stargardt disease, 1,200 ABCA4 mutations, Phase 2/3 enrollment complete, topline mid-2027), and OCU410 (geographic atrophy, Phase 3 initiated 3Q 2026 with ~237 patients, topline 2028). Phase 2 OCU410 showed 31% lesion reduction vs. control; OCU400 Phase 1/2 showed 63% of treated eyes improved at 12 months with durable 3-year data; OCU410ST Phase 1 showed 54% lesion reduction, 100% visual stabilization/improvement, no serious adverse events. All three programs target BLA submission by 2028 with designations including Orphan Drug, RMAT, and ATMP.
Why this rating
Three programs in Phase 2/3 with concrete clinical efficacy and 2028 BLA targets represent material pipeline advancement for $279M company. Moderate relative impact: success contingent on Phase 3 outcomes, regulatory approval uncertain, and company burn rate critical. Not transformational until regulatory approval.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.